Tolerability and Activity of Ublituximab, Umbralisib, and Ibrutinib in Patients with Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma: A Phase 1 Dose Escalation and Expansion Trial

Drug Category : Array
Conference Category : Array
Lead Author : Nastoupil L, et al.
Published Date : 01/02/2019
Download Link : https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30216-3/fulltext
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top